Sarepta Therapeutics SRPT
NASDAQ SRPT
$16.22 -1.02 (-5.92%)
As of: Nov 10, 2026 · 1:46 PM EST

Sarepta Therapeutics (SRPT) Construction in Progress (2013)

Updated

Sarepta Therapeutics (SRPT) recorded Construction in Progress of $11.3 million in Q4 2013.

Analysis

Sarepta Therapeutics (SRPT) Construction in Progress (2013) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn -
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn -
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn -
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn -
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn -
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn -
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn -
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn -
10 Sarepta Therapeutics 1.79 Bn -1.47 Bn 192.84 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2013 11.30 Mn
API Access

Sarepta Therapeutics Construction in Progress API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=construction-in-progress&ticker=SRPT&period=max&api_key=YOUR_API_KEY